


10/725221

-2-


PC27831A

**Amendments to the Claims:**


1. (Currently Amended) A method of treating chronic or neuropathic pain, ~~treating or preventing migraine headache, or treating urge, stress or mixed urinary incontinence~~ comprising administration of an effective amount of a compound selected from one of the Formulae IA, IB, IIA, IIB, IIIA or IIIB




IA




IB




IIA



IIB



IIIA



IIIB

10/725221

-3-

PC27831A

wherein:

R<sup>1</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl and benzyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, -CN, -OR<sup>8</sup> and -NR<sup>8</sup>R<sup>9</sup>;

R<sup>2</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl and C<sub>1</sub>-C<sub>6</sub> haloalkyl;

R<sup>3</sup> is selected from the group consisting of H, halogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>3</sub>-C<sub>6</sub> cycloalkyl, wherein C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> haloalkyl and C<sub>3</sub>-C<sub>6</sub> cycloalkyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from OR<sup>8</sup> and NR<sup>8</sup>R<sup>9</sup>;

R<sup>4</sup>, R<sup>5</sup>, and R<sup>6</sup> are each independently selected at each occurrence thereof from the group consisting of H, halogen, -OR<sup>10</sup>, -NO<sub>2</sub>, -NR<sup>10</sup>R<sup>11</sup>, -NR<sup>10</sup>C(O)R<sup>11</sup>, -NR<sup>10</sup>C(O)NR<sup>11</sup>R<sup>12</sup>, -S(O)<sub>n</sub>R<sup>11</sup>, -CN, -C(O)R<sup>11</sup>, -C(O)<sub>2</sub>R<sup>11</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl and C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, wherein each of C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl and C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl are optionally substituted with 1 to 3 substituents independently selected at each occurrence with from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, =O, -CN, -OR<sup>8</sup>, -NR<sup>8</sup>R<sup>9</sup> and phenyl, and wherein phenyl is optionally substituted 1-3 substituents selected independently at each occurrence from halogen, -CN, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, -OR<sup>8</sup> and -NR<sup>8</sup>R<sup>9</sup>;

alternatively R<sup>5</sup> and R<sup>6</sup> taken together are -O-C(R<sup>11</sup>)<sub>2</sub>-O-;

R<sup>7</sup> is selected from the group consisting of H, halogen and OR<sup>10</sup>;

R<sup>8</sup> and R<sup>9</sup> are each independently selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxyalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxyalkylalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, -C(O)R<sup>12</sup>, phenyl and benzyl, wherein phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy, or R<sup>8</sup> and R<sup>9</sup> are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine ring;

PC27831A US Amend & Response DRAFT 3-10-2006.doc

10/725221

-4-

PC27831A

R<sup>10</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxyalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, -C(O)R<sup>12</sup>, phenyl and benzyl, wherein phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, -NH<sub>2</sub>, -OH, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

R<sup>11</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxyalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, phenyl and benzyl, where phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, -NH<sub>2</sub>, -OH, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy, or R<sup>10</sup> and R<sup>11</sup> are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, N-methylpiperazine, morpholine, or thiomorpholine ring, with the proviso that only one of R<sup>8</sup> and R<sup>9</sup> or R<sup>10</sup> and R<sup>11</sup> are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine ring;

R<sup>12</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and phenyl;

X is selected from the group consisting of O, NR<sup>13</sup> and S;

the ring containing X is selected from furan, pyrrole, thiophene, dihydrofuran, dihydropyrrole, and dihydrothiophene; n is 0, 1, or 2; and,

R<sup>13</sup> is selected from the group consisting of H, C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl and phenyl, wherein C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl and phenyl are optionally substituted with 1-3 substituents independently at each occurrence from halogen, -NH<sub>2</sub>, -OH, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and C<sub>1</sub>-C<sub>4</sub> haloalkoxy;

or a pharmaceutically acceptable salt thereof or an isomer or prodrug thereof to a patient in need thereof.

2. (Original) A method of claim 1, wherein R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl.

3. (Original) A method of claim 2, wherein R<sup>1</sup> is CH<sub>3</sub>.

10/725221

-5-

PC27831A


4. (Original) A method of claim 1, wherein  $R^2$  is H,  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_6$  cycloalkyl, or  $C_1$ - $C_6$  haloalkyl.
5. (Original) A method of claim 4, wherein  $R^2$  is H or  $C_1$ - $C_6$  alkyl.
6. (Original) A method of claim 5, wherein  $R^2$  is H.
7. (Original) A method of claim 1, wherein  $R^3$  is at each occurrence thereof independently H, halogen,  $C_1$ - $C_6$  alkyl, or  $C_1$ - $C_6$  alkyl substituted with from 1 to 3 of  $OR^8$  or  $NR^8R^9$ .
8. (Original) A method of claim 7, wherein  $R^3$  is H or  $C_1$ - $C_6$  alkyl.
9. (Original) A method of claim 8, wherein  $R^3$  is H.
10. (Original) A method of claim 1, wherein  $R^1$  is  $CH_3$ ,  $R^2$  is H and  $R^3$  is H.
11. (Original) A method of claim 1, wherein  $R^4$ ,  $R^5$  and  $R^6$  are each independently H, halogen,  $C_1$ - $C_6$  alkyl or  $-OR^{10}$ .
12. (Original) A method of claim 11, wherein at least one of  $R^4$ ,  $R^5$  and  $R^6$  is H.
13. (Original) A method of claim 12, wherein each of  $R^4$ ,  $R^5$  and  $R^6$  are H.
14. (Original) A method of claim 12, wherein one of  $R^4$ ,  $R^5$  and  $R^6$  is halogen.
15. (Original) A method of claim 1, wherein  $R^1$  is  $CH_3$ ,  $R^2$  and  $R^3$  are each H, and at least one of  $R^4$ ,  $R^5$ , and  $R^6$  is H.

10/725221

-6-

PC27831A


16. (Original) A method of claim 1 wherein the compound is a compound of Formula (10):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (10) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (10) wherein R<sup>4</sup> is H, R<sup>5</sup> is Me and R<sup>6</sup> is H;
- a compound of Formula (10) wherein R<sup>4</sup> is Cl, R<sup>5</sup> is H and R<sup>6</sup> is H; and
- a compound of Formula (10) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H.

17. (Original) A method of claim 1 wherein the compound is a compound of Formula (20):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:


- a compound of Formula (20) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (20) wherein R<sup>4</sup> is H, R<sup>5</sup> is Me and R<sup>6</sup> is H;
- a compound of Formula (20) wherein R<sup>4</sup> is H, R<sup>5</sup> is Cl and R<sup>6</sup> is H;
- a compound of Formula (20) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H; and
- a compound of Formula (20) wherein R<sup>4</sup> is F, R<sup>5</sup> is H and R<sup>6</sup> is F.

10/725221

-7-

PC27831A


18. (Original) A method of claim 1 wherein the compound is a compound of Formula (30):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is F;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is H;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is Cl;
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and
- a compound of Formula (30) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is H.

19. (Original) A method of claim 1 wherein the compound is a compound of Formula (40):



10/725221


-8-

PC27831A

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is F;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is H;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is H;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is Cl and  $R^6$  is F;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F and  $R^6$  is Cl;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H and  $R^6$  is Cl;
- a compound of Formula (40) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H;
- a compound of Formula (40) wherein  $R^3$  is Me,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;
- a compound of Formula (40) wherein  $R^3$  is Et,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H; and
- a compound of Formula (40) wherein  $R^3$  is  $\text{CH}_2\text{OH}$ ,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H.

20. (Original) A method of claim 1 wherein the compound is a compound of Formula (50):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:


- a compound of Formula (50) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H and  $R^6$  is H.

10/725221

-9-

PC27831A

21. (Original) A method of claim 1 wherein the compound is a compound of Formula (60):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Et;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is H;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is Me;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is F and  $R^{13}$  is H;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is F and  $R^{13}$  is Me;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is Cl,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is Cl,  $R^6$  is H and  $R^{13}$  is Me;
- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is H;

and


- a compound of Formula (60) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is Me.

10/725221

-10-

PC27831A

22. (Original) A method of claim 1 wherein the compound is a compound of Formula (70):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Et;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Bn;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is H;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is F and  $R^{13}$  is Me;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is F and  $R^{13}$  is Me;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is H,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is Cl,  $R^6$  is H and  $R^{13}$  is H;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is F,  $R^5$  is Cl,  $R^6$  is H and  $R^{13}$  is Me;
- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is H;

and


- a compound of Formula (70) wherein  $R^3$  is H,  $R^4$  is Cl,  $R^5$  is F,  $R^6$  is H and  $R^{13}$  is Me.

10/725221

-11-

PC27831A


23. (Original) A method of claim 1 wherein the compound is a compound of Formula (80):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (80) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (80) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H; and
- a compound of Formula (80) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F.

24. (Original) A method of claim 1 wherein the compound is a compound of Formula (90):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:


- a compound of Formula (90) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (90) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F; and
- a compound of Formula (90) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H.

10/725221

-12-

PC27831A

25. (Original) A method of claim 1 wherein the compound is a compound of Formula (100):




(100)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (100) wherein R<sup>4</sup> is H, R<sup>5</sup> is H, R<sup>6</sup> is H and R<sup>13</sup> is H.

26. (Original) A method of claim 1 wherein the compound is a compound of Formula (110):



(110)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:


- a compound of Formula (110) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (110) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F;
- a compound of Formula (110) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H;
- a compound of Formula (110) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is Cl;
- a compound of Formula (110) wherein R<sup>4</sup> is H, R<sup>5</sup> is Cl and R<sup>6</sup> is F;
- a compound of Formula (110) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is Cl; and
- a compound of Formula (110) wherein R<sup>4</sup> is H, R<sup>5</sup> is OMe and R<sup>6</sup> is H.

10/725221

-13-

PC27831A

27. (Original) A method of claim 1 wherein the compound is a compound of Formula (120):




(120)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (120) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (120) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F;
- a compound of Formula (120) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H;
- a compound of Formula (120) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is Cl;
- a compound of Formula (120) wherein R<sup>4</sup> is H, R<sup>5</sup> is Cl and R<sup>6</sup> is F;
- a compound of Formula (120) wherein R<sup>4</sup> is H, R<sup>5</sup> is OMe and R<sup>6</sup> is H; and
- a compound of Formula (120) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is Cl.

28. (Original) A method of claim 1 wherein the compound is a compound of Formula (130):



(130)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:


- a compound of Formula (130) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H; and
- a compound of Formula (130) wherein R<sup>4</sup> is H, R<sup>5</sup> is Bn and R<sup>6</sup> is H.

10/725221

-14-

PC27831A

29. (Original) A method of claim 1 wherein the compound is a compound of Formula (140):




(140)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (140) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (140) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H;
- a compound of Formula (140) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is Cl;
- a compound of Formula (140) wherein R<sup>4</sup> is H, R<sup>5</sup> is Cl and R<sup>6</sup> is F;
- a compound of Formula (140) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is Cl;
- a compound of Formula (140) wherein R<sup>4</sup> is H, R<sup>5</sup> is OMe and R<sup>6</sup> is H;
- a compound of Formula (140) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F.

30. (Original) A method of claim 1 wherein the compound is a compound of Formula (150):



(150)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (150) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (150) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H;
- a compound of Formula (150) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is Cl;
- a compound of Formula (150) wherein R<sup>4</sup> is H, R<sup>5</sup> is Cl and R<sup>6</sup> is F;
- a compound of Formula (150) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is Cl;

PC27831A US Amcd & Response DRAFT 3-10-2006.doc

10/725221


-15-

PC27831A

a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is OMe and  $R^6$  is H; and

a compound of Formula (150) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

31. (Original) A method of claim 1 wherein the compound is a compound of Formula (160):




(160)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (160) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H.

32. (Original) A method of claim 1 wherein the compound is a compound of Formula (170):



(170)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is H and  $R^6$  is H;

a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is H; and


a compound of Formula (170) wherein  $R^4$  is H,  $R^5$  is F and  $R^6$  is F.

10/725221

-16-

PC27831A


33. (Original) A method of claim 1 wherein the compound is a compound of Formula (180):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (180) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H;
- a compound of Formula (180) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is H; and
- a compound of Formula (180) wherein R<sup>4</sup> is H, R<sup>5</sup> is F and R<sup>6</sup> is F.

34. (Original) A method of claim 1 wherein the compound is a compound of Formula (190):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:


- a compound of Formula (190) wherein R<sup>4</sup> is H, R<sup>5</sup> is H and R<sup>6</sup> is H.

10/725221

-17-

PC27831A

35. (Original) A method of claim 1 wherein the compound is a compound of Formula (200):



or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (200) wherein  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is H; and
- a compound of Formula (200) wherein  $R^4$  is H,  $R^5$  is H,  $R^6$  is H and  $R^{13}$  is Me.

36. (Original) A method of claim 1 wherein the compound is selected from the group consisting of:

- (R)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-h]isoquinoline;
- (S)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-h]isoquinoline;
- (R)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-g]isoquinoline;
- (S)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-g]isoquinoline;
- (R)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (S)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (R)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (S)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (R)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (S)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (R)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (S)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (R)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-h]isoquinoline;
- (S)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-h]isoquinoline;
- (R)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (S)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (R)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;

10/725221

-18-

PC27831A

(S)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(R)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-h]isoquinoline; and  
(S)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-h]isoquinoline.

37. (Original) A method of claim 1 wherein the compound is selected from the group consisting of:

(+)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-h]isoquinoline;  
(-)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-h]isoquinoline;  
(+)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-g]isoquinoline;  
(-)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-g]isoquinoline;  
(+)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(-)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(+)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(-)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(+)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(-)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(+)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(-)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(+)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2h]isoquinoline;  
(-)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2h]isoquinoline;  
(+)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(-)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(+)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(-)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;  
(+)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-h]isoquinoline; and  
(-)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-h]isoquinoline.